Literature DB >> 30707047

Talin-Dependent Integrin Activation Regulates VE-Cadherin Localization and Endothelial Cell Barrier Function.

Fadi E Pulous1,2, Cynthia M Grimsley-Myers3, Shevali Kansal1, Andrew P Kowalczyk4,5, Brian G Petrich1.   

Abstract

RATIONALE: Endothelial barrier function depends on the proper localization and function of the adherens junction protein VE (vascular endothelial)-cadherin. Previous studies have suggested a functional relationship between integrin-mediated adhesion complexes and VE-cadherin yet the underlying molecular links are unclear. Binding of the cytoskeletal adaptor protein talin to the β-integrin cytoplasmic domain is a key final step in regulating the affinity of integrins for extracellular ligands (activation) but the role of integrin activation in VE-cadherin mediated endothelial barrier function is unknown.
OBJECTIVE: To test the requirement of talin-dependent activation of β1 integrin in VE-cadherin organization and endothelial cell (EC) barrier function. METHODS AND
RESULTS: EC-specific deletion of talin in adult mice resulted in impaired stability of intestinal microvascular blood vessels, hemorrhage, and death. Talin-deficient endothelium showed altered VE-cadherin organization at EC junctions in vivo. shRNA (short hairpin RNA)-mediated knockdown of talin1 expression in cultured ECs led to increased radial actin stress fibers, increased adherens junction width and increased endothelial monolayer permeability measured by electrical cell-substrate impedance sensing. Restoring β1-integrin activation in talin-deficient cells with a β1-integrin activating antibody normalized both VE-cadherin organization and EC barrier function. In addition, VE-cadherin organization was normalized by reexpression of talin or integrin activating talin head domain but not a talin head domain mutant that is selectively deficient in activating integrins.
CONCLUSIONS: Talin-dependent activation of EC β1-integrin stabilizes VE-cadherin at endothelial junctions and promotes endothelial barrier function.

Entities:  

Keywords:  cadherins; cytoskeleton; endothelium; integrins; talin

Mesh:

Substances:

Year:  2019        PMID: 30707047      PMCID: PMC6521868          DOI: 10.1161/CIRCRESAHA.118.314560

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  55 in total

1.  Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice.

Authors:  Mara E Pitulescu; Inga Schmidt; Rui Benedito; Ralf H Adams
Journal:  Nat Protoc       Date:  2010-08-12       Impact factor: 13.491

Review 2.  Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates.

Authors:  Ravid Shechter; Anat London; Michal Schwartz
Journal:  Nat Rev Immunol       Date:  2013-03       Impact factor: 53.106

Review 3.  The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces.

Authors:  Keeley L Mui; Christopher S Chen; Richard K Assoian
Journal:  J Cell Sci       Date:  2016-02-26       Impact factor: 5.285

Review 4.  Molecular mechanism of inside-out integrin regulation.

Authors:  Feng Ye; Chungho Kim; Mark H Ginsberg
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

5.  Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

Authors:  Yunlong Yang; Yin Zhang; Ziquan Cao; Hong Ji; Xiaojuan Yang; Hideki Iwamoto; Eric Wahlberg; Toste Länne; Baocun Sun; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

Review 6.  Integrin function in vascular biology: a view from 2013.

Authors:  Edward F Plow; Julia Meller; Tatiana V Byzova
Journal:  Curr Opin Hematol       Date:  2014-05       Impact factor: 3.284

7.  Integrin signaling is critical for pathological angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Weiyi Feng; David R Phillips; Tatiana V Byzova
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

8.  Blocking neutrophil integrin activation prevents ischemia-reperfusion injury.

Authors:  Tadayuki Yago; Brian G Petrich; Nan Zhang; Zhenghui Liu; Bojing Shao; Mark H Ginsberg; Rodger P McEver
Journal:  J Exp Med       Date:  2015-07-13       Impact factor: 14.307

9.  The F-BAR protein pacsin2 inhibits asymmetric VE-cadherin internalization from tensile adherens junctions.

Authors:  Yvonne L Dorland; Tsveta S Malinova; Anne-Marieke D van Stalborch; Adam G Grieve; Daphne van Geemen; Nicolette S Jansen; Bart-Jan de Kreuk; Kalim Nawaz; Jeroen Kole; Dirk Geerts; René J P Musters; Johan de Rooij; Peter L Hordijk; Stephan Huveneers
Journal:  Nat Commun       Date:  2016-07-15       Impact factor: 14.919

10.  Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo.

Authors:  Bernhard Nieswandt; Markus Moser; Irina Pleines; David Varga-Szabo; Sue Monkley; David Critchley; Reinhard Fässler
Journal:  J Exp Med       Date:  2007-12-17       Impact factor: 14.307

View more
  21 in total

1.  A discrete interface in matrix stiffness creates an oscillatory pattern of endothelial monolayer disruption.

Authors:  Jacob A VanderBurgh; Archit V Potharazu; Samantha C Schwager; Cynthia A Reinhart-King
Journal:  J Cell Sci       Date:  2020-09-17       Impact factor: 5.285

2.  [Talin1 is highly expressed in the fallopian tube and chorionic villi to promote trophoblast invasion in tubal pregnancy].

Authors:  P Qiu; X Lin; G Deng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

3.  Integrin affinity modulation critically regulates atherogenic endothelial activation in vitro and in vivo.

Authors:  Zaki Al-Yafeai; Brenna H Pearson; Jonette M Peretik; Elizabeth D Cockerham; Kaylea A Reeves; Umesh Bhattarai; Dongdong Wang; Brian G Petrich; A Wayne Orr
Journal:  Matrix Biol       Date:  2020-11-04       Impact factor: 11.583

Review 4.  Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies.

Authors:  Lena Claesson-Welsh; Elisabetta Dejana; Donald M McDonald
Journal:  Trends Mol Med       Date:  2020-12-10       Impact factor: 11.951

Review 5.  β1- and β2-integrins: central players in regulating vascular permeability and leukocyte recruitment during acute inflammation.

Authors:  Ziwei Ou; Elena Dolmatova; Bernard Lassègue; Kathy K Griendling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-12-18       Impact factor: 4.733

6.  Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis.

Authors:  Yi-Yi Wang; Hua Duan; Sha Wang; Yong-Jun Quan; Jun-Hua Huang; Zheng-Chen Guo
Journal:  Reprod Biol Endocrinol       Date:  2021-05-14       Impact factor: 5.211

7.  Pathological Angiogenesis Requires Syndecan-4 for Efficient VEGFA-Induced VE-Cadherin Internalization.

Authors:  Giulia De Rossi; Maria Vähätupa; Enrico Cristante; Samantha Arokiasamy; Sidath E Liyanage; Ulrike May; Laura Pellinen; Hannele Uusitalo-Järvinen; James W Bainbridge; Tero A H Järvinen; James R Whiteford
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-18       Impact factor: 10.514

8.  c-Src controls stability of sprouting blood vessels in the developing retina independently of cell-cell adhesion through focal adhesion assembly.

Authors:  Lilian Schimmel; Daisuke Fukuhara; Mark Richards; Yi Jin; Patricia Essebier; Emmanuelle Frampton; Marie Hedlund; Elisabetta Dejana; Lena Claesson-Welsh; Emma Gordon
Journal:  Development       Date:  2020-04-06       Impact factor: 6.868

Review 9.  Integrin-dependent regulation of the endothelial barrier.

Authors:  Fadi E Pulous; Brian G Petrich
Journal:  Tissue Barriers       Date:  2019-11-05

10.  Talin-dependent integrin activation is required for endothelial proliferation and postnatal angiogenesis.

Authors:  Fadi E Pulous; Jamie C Carnevale; Zaki Al-Yafeai; Brenna H Pearson; Jamie A G Hamilton; Curtis J Henry; A Wayne Orr; Brian G Petrich
Journal:  Angiogenesis       Date:  2020-10-28       Impact factor: 10.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.